Checkpoint Therapeutics, Inc. (CKPT) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). An upward trend in earnings estimates -- one of the most powerful ...
Checkpoint Therapeutics, Inc.'s cosibelimab shows promising efficacy and safety in treating cSCC, with a high tumor occupancy rate and strong clinical data. The upcoming PDUFA date on December 28th is ...
Checkpoint Therapeutics' Cosibelimab, an anti-PD-L1 antibody, shows promise for treating cSCC, with potential FDA approval by December 2024, making CKPT a speculative "buy." Cosibelimab's dual ...
A look at the shareholders of Checkpoint Therapeutics, Inc. (NASDAQ:CKPT) can tell us which group is most powerful. With 56% stake, individual investors possess the maximum shares in the company. In ...
Fintel reports that on January 13, 2025, D. Boral Capital initiated coverage of Checkpoint Therapeutics (NasdaqCM:CKPT) with a Buy recommendation. As of December 23, 2024, the average one-year price ...
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced it has entered into a definitive agreement with a single ...
Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a clinical-stage immunotherapy and targeted oncology company, today announced that the U.S. Food and Drug Administration (“FDA”) has ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results